BioFocus Extends its Collaboration with The Michael J. Fox Foundation
News Apr 18, 2013
BioFocus has announced that it has extended its collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.
Based on the success of the project to date, BioFocus will continue the optimization of agents for disease specific biomarkers.
“We have worked with The Michael J. Fox Foundation since 2011 to identify and optimize a-synuclein imaging agents, and are delighted that the progress supports an extension to this collaboration,” said Dr Chris Newton, Managing Director, BioFocus.
Dr Newton continued, “The program will utilize BioFocus' leading biology and chemistry platforms, and will capitalize on the company’s highly experienced teams and state-of-the-art technologies.”
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Scientists have long known that circulating tumor cells, rare cancer cells that are released into the bloodstream, have the potential to provide vital information about a person's specific cancer. Researchers have now created an effective mechanism to measure how these cells perform functions that drive the disease.READ MORE